Journal of Dermatology最新文献

{"title":"Predictive factors for responders to deucravacitinib treatment in patients with psoriasis","authors":"Teppei Hagino,&nbsp;Marina Onda,&nbsp;Hidehisa Saeki,&nbsp;Eita Fujimoto,&nbsp;Naoko Kanda","doi":"10.1111/1346-8138.17601","DOIUrl":"10.1111/1346-8138.17601","url":null,"abstract":"<p>The tyrosine kinase 2 inhibitor deucravacitinib is therapeutically effective for psoriasis. However, predictive factors for high responses to deucravacitinib have not been examined in a real-world clinical study. Our study aimed to identify predictive factors for responders to deucravacitinib. Therefore, a retrospective study was conducted on 74 patients with psoriasis treated with deucravacitinib (6 mg/day) at week 16 of treatment from January 2023 to February 2024. Patients were classified into responders (achievers of a static Physician's Global Assessment [sPGA] of 0 or 1 with ≥2-point improvement from basal sPGA) and non-responders (non-achievers). We compared baseline values of clinical and laboratory indexes between responders and non-responders. Multivariate logistic regression analysis was used to identify variables predicting responders. Forty-one patients (55.4%) were considered as responders at week 16. Multivariate logistic regression analysis revealed that the response to deucravacitinib was associated with higher age (odds ratio [OR] 1.04; 95% confidence interval [CI] 1.01–1.08; <i>p</i> = 0.0222) and lower body mass index (BMI) (OR 0.825; 95% CI 0.713–0.955; <i>p</i> = 0.0101). Higher age and lower BMI may predict a higher response to deucravacitinib (6 mg/day) at week 16 of treatment.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 3","pages":"551-555"},"PeriodicalIF":2.9,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142901497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Wound, Pressure Ulcer, and Burn Guidelines-5: Guidelines for the management of lower leg ulcers and varicose veins, second edition","authors":"Takaaki Ito,&nbsp;Ryuichi Kukino,&nbsp;Yasuko Sarayama,&nbsp;Miki Tanioka,&nbsp;Takeo Maekawa,&nbsp;Hiroshi Yatsushiro,&nbsp;Jun Asai,&nbsp;Yoshihide Asano,&nbsp;Masatoshi Abe,&nbsp;Masahiro Amano,&nbsp;Ryuta Ikegami,&nbsp;Takayuki Ishii,&nbsp;Taiki Isei,&nbsp;Zenzo Isogai,&nbsp;Yuji Inoue,&nbsp;Ryokichi Irisawa,&nbsp;Yohei Iwata,&nbsp;Masaki Otsuka,&nbsp;Yoichi Omoto,&nbsp;Hiroshi Kato,&nbsp;Hideaki Tanizaki,&nbsp;Takafumi Kadono,&nbsp;Sakae Kaneko,&nbsp;Hiroyuki Kanoh,&nbsp;Tamihiro Kawakami,&nbsp;Masakazu Kawaguchi,&nbsp;Takeshi Kono,&nbsp;Monji Koga,&nbsp;Masanari Kodera,&nbsp;Keisuke Sakai,&nbsp;Eiichi Sakurai,&nbsp;Yoichi Shintani,&nbsp;Jun Tsujita,&nbsp;Naotaka Doi,&nbsp;Takeshi Nakanishi,&nbsp;Akira Hashimoto,&nbsp;Minoru Hasegawa,&nbsp;Masahiro Hayashi,&nbsp;Kuninori Hirosaki,&nbsp;Hideki Fujita,&nbsp;Manabu Fujimoto,&nbsp;Hiroshi Fujiwara,&nbsp;Koma Matsuo,&nbsp;Naoki Madokoro,&nbsp;Sei-Ichiro Motegi,&nbsp;Osamu Yamasaki,&nbsp;Yuichiro Yoshino,&nbsp;Andres Le Pavoux,&nbsp;Takao Tachibana,&nbsp;Hironobu Ihn","doi":"10.1111/1346-8138.17503","DOIUrl":"10.1111/1346-8138.17503","url":null,"abstract":"<p>“Wound, Pressure Ulcer, and Burn Guidelines-5: Guidelines for the management of lower leg ulcers and varicose veins, second edition” is revised from the first edition, which was published in the <i>Japanese Journal of Dermatology</i> in 2011. The guidelines were drafted by the Wound, Pressure Ulcer, and Burn Guidelines Drafting Committee delegated by the Japanese Dermatological Association and intend to facilitate physicians' clinical decisions in preventing, diagnosing and management of lower leg ulcers and varicose veins. We updated all sections by collecting documents published since the publication of the first edition. In particular, we added clinical question 8 (CQ8), which addresses endovenous laser ablation for varicose veins, a procedure that became covered by the Japanese national health insurance after the writing of the first edition, and endovenous radiofrequency ablation, which became covered by national health insurance in 2014. We also rearranged the subsequent clinical question (CQs) for easier reading. While the addition of these new techniques has increased the number of options available within the treatment algorithm, differences have arisen in the indication for surgery depending on the facility performing the treatment. Therefore, these have been abbreviated.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 2","pages":"e49-e69"},"PeriodicalIF":2.9,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1346-8138.17503","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142901498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advanced phasing techniques in congenital skin diseases","authors":"Ken Natsuga","doi":"10.1111/1346-8138.17597","DOIUrl":"10.1111/1346-8138.17597","url":null,"abstract":"<p>Phasing, the process of determining which alleles at different loci on homologous chromosomes belong together on the same chromosome, is crucial in the diagnosis and management of autosomal recessive diseases. Advances in long-read sequencing technologies have significantly enhanced our ability to accurately determine haplotypes. This review discusses the application of low-coverage long-read sequencing, nanopore Cas9-guided long-read sequencing, and adaptive sampling in phasing, highlighting their utility in complex clinical scenarios. Through clinical vignettes, we explore the importance of phasing in gene therapy design for recessive dystrophic epidermolysis bullosa and the role of revertant mosaicism in therapeutic epidermal autografts. Despite its promise, phasing with long-read sequencing faces challenges, including low efficiency in enriching target regions and the inherent error rate of nanopore sequencing. Future developments in long-read sequencing technologies will be critical in overcoming these limitations and expanding the applicability of phasing across various clinical settings.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 3","pages":"392-399"},"PeriodicalIF":2.9,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1346-8138.17597","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142901451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Protruding nodular fasciitis on the face","authors":"Honami Akanabe,&nbsp;Kana Tanahashi,&nbsp;Shoichiro Mori,&nbsp;Yoshie Murakami,&nbsp;Toru Motoi,&nbsp;Masashi Akiyama","doi":"10.1111/1346-8138.17591","DOIUrl":"10.1111/1346-8138.17591","url":null,"abstract":"","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 4","pages":"e321-e322"},"PeriodicalIF":2.9,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142883913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CYLD novel splicing mutation in a patient with CYLD cutaneous syndrome with basal cell carcinomas","authors":"Jiro Nishio,&nbsp;Naohito Hatta,&nbsp;Takayuki Ishii,&nbsp;Keiko Yamamoto,&nbsp;Fumiaki Shirasaki,&nbsp;Sumihito Togi,&nbsp;Hiroki Ura,&nbsp;Yo Niida","doi":"10.1111/1346-8138.17584","DOIUrl":"10.1111/1346-8138.17584","url":null,"abstract":"","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 4","pages":"e311-e312"},"PeriodicalIF":2.9,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142883896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Odontogenic infection as a possible trigger of palmoplantar pustulosis with extensive extra-palmoplantar involvement and subsequent development of IgA vasculitis: A case report","authors":"Nobuyuki Kikuchi,&nbsp;Maki Takada,&nbsp;Natsumi Norikawa,&nbsp;Miyuki Yamamoto,&nbsp;Masato Ishikawa,&nbsp;Toshiyuki Yamamoto","doi":"10.1111/1346-8138.17599","DOIUrl":"10.1111/1346-8138.17599","url":null,"abstract":"","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 5","pages":"e341-e342"},"PeriodicalIF":2.9,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142883902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"English version of clinical practice guidelines for the management of atopic dermatitis 2024","authors":"Hidehisa Saeki,&nbsp;Yukihiro Ohya,&nbsp;Hirokazu Arakawa,&nbsp;Susumu Ichiyama,&nbsp;Toshio Katsunuma,&nbsp;Norito Katoh,&nbsp;Akio Tanaka,&nbsp;Hideaki Tanizaki,&nbsp;Yuichiro Tsunemi,&nbsp;Takeshi Nakahara,&nbsp;Mizuho Nagao,&nbsp;Masami Narita,&nbsp;Michihiro Hide,&nbsp;Takao Fujisawa,&nbsp;Masaki Futamura,&nbsp;Koji Masuda,&nbsp;Tomoyo Matsubara,&nbsp;Hiroyuki Murota,&nbsp;Kiwako Yamamoto-Hanada,&nbsp;Junichi Furuta","doi":"10.1111/1346-8138.17544","DOIUrl":"10.1111/1346-8138.17544","url":null,"abstract":"<p>This is the English version of the 2024 clinical practice guidelines for the management of atopic dermatitis (AD). AD is a disease characterized by relapsing eczema with pruritus as a primary lesion. A crucial aspect of AD treatment is the prompt induction of remission via the suppression of existing skin inflammation and pruritus. To achieve this, topical anti-inflammatory drugs, such as topical corticosteroids, tacrolimus ointment, delgocitinib ointment, and difamilast ointment, have been used. However, the following treatments should be considered in addition to topical therapy for patients with refractory moderate-to-severe AD: oral cyclosporine, subcutaneous injections of biologics (dupilumab, nemolizumab, tralokinumab), oral Janus kinase inhibitors (baricitinib, upadacitinib, abrocitinib), and phototherapy. In these revised guidelines, descriptions of five new drugs, namely, difamilast, nemolizumab, tralokinumab, upadacitinib, and abrocitinib, have been added. The guidelines present recommendations to review clinical research articles, evaluate the balance between the advantages and disadvantages of medical activities, and optimize medical activity-related patient outcomes with respect to several important points requiring decision-making in clinical practice.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 2","pages":"e70-e142"},"PeriodicalIF":2.9,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1346-8138.17544","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142873732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inflammatory proteins and hidradenitis suppurativa: Insights from genetic correlation and Mendelian randomization","authors":"Hui Luo,&nbsp;Yang Chen,&nbsp;Jianrong Li,&nbsp;Yanmei Yang,&nbsp;Xiujun Wang,&nbsp;Ping Yang,&nbsp;Chuang Guo,&nbsp;Fei Liu","doi":"10.1111/1346-8138.17590","DOIUrl":"10.1111/1346-8138.17590","url":null,"abstract":"<p>Previous research has highlighted a significant association between inflammatory proteins and the development and progression of hidradenitis suppurativa (HS). Nevertheless, the potential causative link between these factors remains to be definitively established. To investigate the genetic correlation between inflammatory proteins and HS, linkage disequilibrium score regression (LDSC) was employed. Mendelian randomization (MR) analysis, incorporating inverse variance weighted, MR-Egger, and weighted median methodologies, was utilized to evaluate the possible causal relationship between circulating inflammatory proteins (CIPs) and HS. Additionally, reverse MR analysis was carried out to explore reverse causality. The data set for 91 CIPs was derived from a genome-wide protein quantitative trait loci study, while HS-related data were acquired from the FinnGen study. Moreover, the stability of the causal relationships was assessed via sensitivity analyses, encompassing tests for pleiotropy, heterogeneity, and leave-one-out analysis. The LDSC analysis suggested the existence of genetic correlations between the levels of Fibroblast growth factor 21 (FGF-21), stem cell factor, and HS. The MR analysis identified a suggestive association of T-cell surface glycoprotein CD5 and C-X-C motif chemokine 11 with an elevated risk of HS. Conversely, C-C motif chemokine 4, Protein S100-A12, Interleukin-10 receptor subunit beta, and Programmed cell death 1 ligand 1 were associated with a diminished risk of HS. Moreover, HS was demonstrated to increase the levels of four CIPs: Interleukin-20, Leukemia inhibitory factor (LIF), LIF receptor, and Thymic stromal lymphopoietin. The findings of this investigation offer suggestive evidence for possible genetic correlations and causal links between various genetically predicted inflammatory proteins and HS. There exists a pressing requirement for additional studies to elucidate the fundamental processes driving these associations.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 3","pages":"481-492"},"PeriodicalIF":2.9,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142866916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Traumatic experiences, dissociative symptoms, and alexithymia in patients with alopecia areata","authors":"Furkan Demirgil,&nbsp;Nesim Kuğu,&nbsp;Yavuz Yılmaz","doi":"10.1111/1346-8138.17572","DOIUrl":"10.1111/1346-8138.17572","url":null,"abstract":"<p>Although genetic, environmental, autoimmune, and psychological factors are believed to play a role in the onset of alopecia areata (AA), the exact cause remains unknown. This study aimed to investigate whether there are differences in traumatic experiences, dissociative symptoms, and alexithymia levels between groups. Fifty eight patients diagnosed with AA, 58 individuals with dermatological diseases thought to have a low psychosomatic component, and 58 individuals not diagnosed with any chronic disease were included in the study. All participants were assessed using the Childhood Trauma Questionnaire (CTQ-28), Dissociative Experiences Scale (DES), Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5), and Toronto Alexithymia Scale (TAS-20). A Structured Clinical Interview for DSM-5 (SCID-5-CV) form was used to exclude additional psychiatric diagnoses. Mean scores on the CTQ-28 scale revealed differences between groups in terms of physical neglect and emotional neglect scores (<i>p</i> &lt; 0.001; <i>p</i> = 0.022; <i>p</i> &lt; 0.001). There were no differences in DES scores between groups (<i>p</i> = 0.085). When compared in terms of TAS-20 and PCL-5 scores, differences were found (<i>p</i> = 0.016; <i>p</i> = 0.024). As a result of this study, it was concluded that physical neglect and emotional neglect could play a significant role in the onset of AA. Alexithymia and traumatic stress disorder symptoms might be more prevalent in patients with AA.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 3","pages":"452-459"},"PeriodicalIF":2.9,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142857291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nemolizumab-induced exacerbation of atopic dermatitis","authors":"Hirofumi Kamada,&nbsp;Nobuyuki Arakawa,&nbsp;Marino Kato,&nbsp;Takayuki Tanji,&nbsp;Daisuke Watabe,&nbsp;Naoki Yanagawa,&nbsp;Hiroo Amano","doi":"10.1111/1346-8138.17589","DOIUrl":"10.1111/1346-8138.17589","url":null,"abstract":"","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 4","pages":"e316-e318"},"PeriodicalIF":2.9,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142857315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}